| 1 |
26191484 | IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders. | 2015 |
2 |
| 2 |
25349647 | Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis. | 2014 Oct 27 |
1 |
| 3 |
23328301 | IL28B in the era of direct-acting antivirals for hepatitis C. | 2013 Mar |
1 |
| 4 |
23542783 | Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response. | 2013 Jul |
1 |
| 5 |
24000086 | Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients. | 2013 Oct |
2 |
| 6 |
22967098 | Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection? | 2012 Oct |
1 |